GROWTH / DIRECT CATALOG PRICING
IGF-1 LR3
Long R3 IGF-1 is an engineered insulin-like growth factor-1 analogue with an Arg substitution at position 3 and an N-terminal extension; it was designed to have reduced affinity for IGF-binding proteins.
- Format
- Lyophilized research vial
- Listed formats
- 2
- Available now
- 2
- Catalog class
- Growth
Choose a listed format
- 100 mcg$23.00 · AvailableSelect format
- 1 mg$51.00 · AvailableSelect format
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Long R3 IGF-1 is an engineered insulin-like growth factor-1 analogue with an Arg substitution at position 3 and an N-terminal extension; it was designed to have reduced affinity for IGF-binding proteins.
The growth classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Growth
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- 2 formats currently orderable
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Long R3 IGF-1 is an engineered insulin-like growth factor-1 analogue with an Arg substitution at position 3 and an N-terminal extension; it was designed to have reduced affinity for IGF-binding proteins.
- Research covered
- Published studies evaluated Long R3 IGF-1 in guinea pigs, bovine follicle culture, and mammalian cell-culture systems. These models examined binding-protein interactions, receptor activation, and growth-related laboratory endpoints.
- Important limit
- The located evidence is animal or in-vitro evidence, not a human clinical evaluation. It does not verify the catalog's 100 mcg or 1 mg material, and cell-culture potency cannot be translated into human outcomes.
FACTUAL FAQ
IGF-1 LR3 catalog questions
What formats are currently listed?
100 mcg, 1 mg. Current price and stock state appear above.
What did researchers study?
Published studies evaluated Long R3 IGF-1 in guinea pigs, bovine follicle culture, and mammalian cell-culture systems. These models examined binding-protein interactions, receptor activation, and growth-related laboratory endpoints.
What is the most important evidence limit?
The located evidence is animal or in-vitro evidence, not a human clinical evaluation. It does not verify the catalog's 100 mcg or 1 mg material, and cell-culture potency cannot be translated into human outcomes.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →